

April 10, 2024



351 N. Sumneytown Pike
P.O. Box 1000
UG4B-35
North Wales, PA 19454-2505
T: 267-305-1609
E: yvonne.osirim@merck.com

[merck.com](https://www.merck.com)

Act 193 Notification to Vermont Attorney General Introduction of New Prescription Drug

Pursuant to Act 193 of Vermont Law, Merck Sharp & Dohme LLC ("Merck") is providing notice that the prescription drug, WINREVAIR (sotatercept-csrk), is commercially available as of April 8, 2024. The catalog price (WAC) of this drug exceeds the threshold set for a specialty drug under Medicare Part D.

In accordance with Vermont law, Merck will provide additional information required by Act 193 within 30 days of the commercial availability date.

Sincerely,

A handwritten signature in blue ink, appearing to read "Yvonne O. Osirim".

Yvonne O. Osirim
Vice President, Human Health Ethics & Compliance